Emergent BioSolutions (EBS) Net Income towards Common Stockholders (2011 - 2026)

Emergent BioSolutions' Net Income towards Common Stockholders history runs 15 years deep, the most recent figure standing at $6.8 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 90.0% year-over-year to $6.8 million in Q1 2026; TTM through Mar 2026 was -$8.6 million, a 93.47% increase from a year earlier, with the FY2025 full-year figure at $52.6 million, up 127.6% from the prior year.
• Net Income towards Common Stockholders rose to $6.8 million in Q1 2026 per EBS's latest filing, from -$54.6 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $114.8 million in Q3 2024 and bottomed at -$283.1 million in Q2 2024.
• The 5-year median for Net Income towards Common Stockholders is -$49.5 million (2023), against an average of -$65.1 million.
• Across the five-year window, Net Income towards Common Stockholders slumped 4932.43% in 2023 and soared 655.56% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$67.0 million in 2022, then gained by 26.12% to -$49.5 million in 2023, then jumped by 36.77% to -$31.3 million in 2024, then sank by 74.44% to -$54.6 million in 2025, then soared by 112.45% to $6.8 million in 2026.
• Per Business Quant, the three latest EBS Net Income towards Common Stockholders figures stand at $6.8 million (Q1 2026), -$54.6 million (Q4 2025), and $51.2 million (Q3 2025).